As demonstrated by several studies, the pan-inhibitory peptide somatostatin (SS) is implicated in a large variety of physiological processes in the gastrointestinal tractus. SS inhibits hormonal and gastric acid secretions, and decreases gastric and intestinal motility, mesenteric blood flow and intestinal absorption. In vitro and in vivo studies showed also that the antiproliferative potency of SS analogs may be a target to improve the prognosis of colorectal cancer. Here we report the expression profile of the five SS receptor subtypes (hsst1-5) mRNAs in a large set of tumoral and normal colon. Using reverse transcription-PCR, we showed that hsst5, hsst1 and hsst2 mRNA subtypes were the most frequently expressed hsst mRNA subtypes in normal and pathological colon. Interestingly, we found that the frequency of hsst5 mRNA expression in the left colon was significantly higher in tumors than in normal samples: 81.2% (13/16) and 36.4% (4/11) respectively (0.025 > P > 0.01, x 2 test with Yates' correction). We did not find any influence of Dukes' stage on hsst mRNAs expression. Of interest, no loss of hsst2 and hsst5 mRNA expression in advanced stages was noted. Some differences in the frequency of expression of hsst mRNAs according to the origin of the tissue (left or right colon) were evident. The expression of hsst5 and hsst2 mRNA in advanced colorectal carcinoma associated with the development of new SS analogs boost the relevance of colorectal cancer treatment by somatostatin analogs.
Introduction
Despite progress in cancer treatment, colorectal cancer remains one of the most important public health problems. For the advanced stages, the failure of conventional therapies to improve the prognosis of patients needs urgent alternative approaches. A new treatment modality may involve the use of analogs of the ubiquitous pan-inhibitory peptide somatostatin (SS). In the gastrointestinal tract, SS inhibits hormone secretion and gastric acid secretion, and decreases gastric and intestinal motility, mesenteric blood flow and intestinal absorption (1) . In addition, SS can inhibit cell proliferation in a wide variety of cell types. The antiproliferative effects of SS are mediated both indirectly through inhibition of the release of various hormones and growth factors which promote cell growth, through inhibition of angiogenesis, and directly through SS receptors located on tumor tissue inducing an inactivation of growth factors or an activation of programmed cell death (2, 3) . SS and its analogs inhibit in vivo and in vitro tumoral colon cell proliferation and metastatic development (4, 5) . However, patients with advanced colorectal cancer treated with SS analogs did not present significant benefits although their tumoral markers decreased (6, 7) .
The actions of SS are mediated via membrane-bound receptors coupled to GTP binding protein. Five SS receptors of seven transmembrane domains termed hsst1-5 have been cloned (3) . They are all negatively coupled to adenylate cyclase and can also modulate guanidylate cyclase, calcium or potassium channels, activate protein phosphatase, transmodulate tyrosine kinase type receptors and act on the mitogen activated protein kinase (MAP kinase) signaling pathway and even induce apoptosis (3, 8) .
Binding assays and autoradiographic studies have shown the presence of hsst in most hormone-producing tumors as well as in lymphomas and adenocarcinomas originating from breast, prostate, ovary, kidney or colon. 
Materials and methods

Materials
Fifty-three samples of colorectal cancers (primary tumor) and forty-six morphologically normal mucosae (taken from the same patient at a minimal distance of 5 cm from the diseased area) were obtained during surgery and frozen in liquid nitrogen. All patients gave their written consent to participate in the study which was approved by the local ethics committee (Marseilles I). Colon carcinomas were staged according to the Dukes' classification system (15) Table 1 . Immunohistological study of epidermal growth factor receptors (EGF-R) was performed (ab-2, Calbiochem, La Jolla, CA, USA): ++ corresponds to a high level of EGF-R + corresponds to a moderate level, and Ϯ corresponds to a low level of EGF-R. Ki67 immuno-detection (Dako, Copenhagen, Denmark) is given as a percentage of positive nuclei. Mutations of the apoptotic protein P53 were detected with 3 monoclonal anti-P53 antibodies (MAB 1801, Calbiochem; MAB 240, Novocastra (Newcastle, UK); DO7, ab-1, Novocastra) ( Table 1) .
RNA extraction and reverse transcription
Total RNA was isolated as described by Chomczynsky and Sacchi (16) . Since the somatostatin receptor genes lack intronic sequences, the RNA (10 mg) was treated with 10 U RNase free DNase I-RQI (Promega, Madison, WI, USA) for 2 h at 37 ЊC. RT reaction was performed as described by the manufacturer (Life Technologies, Gaithersburg, MD, USA). Briefly, each sample was split in one positive reaction with reverse transcriptase and one control reaction without reverse transcriptase to check for DNA contamination.
Polymerase chain reaction
RNA integrity was verified by co-amplification of the hsst with the constitutively expressed cyclophilin mRNA. Each primer couple was used at 1 mmol final concentration, with 200 mmol of each dNTP and 200 U Expand long template PCR system polymerase (Boehringer, Mannheim, Germany) in 50 ml 1 × manufacturer's buffer. Optimal temperature and cycling conditions were as follows.
hsst1 PCR products were resolved on 1% agarose gels, stained with ethidium bromide and visualized by UV transillumination (Fig. 1) . Specificity of the PCR product was confirmed by Southern blotting and hybridization with the corresponding cDNAs as previously described (17) . All samples were tested for DNA contamination. PCR samples positive without reverse transcriptase treatment were systematically discarded from the study.
Statistical analysis was performed using the x 2 test with Yates' correction.
Results
We found that 85% of normal tissues and 97% of tumors expressed at least one hsst mRNA subtype. The subtypes hsst5, hsst2 and hsst1 were the more frequently expressed, respectively at 68.6%, 54.7% and 56.6% in the tumoral samples and at 48.8%, 60.8% and 41.3% in the normal tissues (Table 2 ). hsst3 and hsst4 mRNA subtypes were less frequently expressed both in tumors, at 15.2%, and 16.9% respectively and in normal tissues at 17.9% and 8.7% respectively. We did not find any influence of Dukes' stages on the hsst mRNAs expression profile. Furthermore, there was no loss of hsst2 mRNA expression in the advanced hsst receptors mRNA in human colorectal cancer 363 colorectal cancers. Interestingly, the high frequency of hsst5 expression was retained in advanced tumors.
No correlation was found between tumor characteristics and immunohistological markers except for P53 mutation which was more frequent in the rectum and the left colon than in the right colon. Moreover, no correlation could be observed between the tumor markers and the hsst mRNAs expression. Some 
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F, female; M, male; nd, not determined; Rec, Rectum; LC, left colon; RC, right colon. * Stage according to Dukes' classification. † Grade is degree of differentiation: HD, hyperdifferentiated; WD, well differentiated; MD, moderately differentiated; UD, undifferentiated. ‡ EGF-R: semiquantitative immunohistochemical detection (ab-2): þþ, high levels; þ, moderate levels; Ϯ, low levels; ¹, negative, § P53: positive (þ) or negative (¹) immunohistochemical detection of the apoptotic protein P53 mutations with 3 monoclonal anti-P53 antibodies (MAB 1801; MAB 240; DO7, ab-1). # Ki67: percentage of positive nuclei.
differences in the expression of hsst mRNAs were seen according to the origin of the tissue. We found that the frequency of hsst5 mRNA expression was significantly higher in tumors than in normal samples in the left colon: 81.2% (13/16) and 36.4% (4/11) respectively (0.025 > P > 0.01). In normal colon, we found that hsst1 mRNA expression decreased throughout the right colon, left colon and rectum and was significantly higher in right colon than in rectum: 66.6% (8/12) and 28.6% (6/21) respectively (0.05 > P > 0.025). The frequency of hsst4 mRNA detection was low in left colon and rectum. hsst4 mRNA was below the level of detection in right colon. Larger series will be useful to confirm these results.
Discussion
Looking for the pathophysiological bases for treatment of colorectal cancer with SS analogs, we found that the five hsst mRNAs were expressed in normal and pathological colon, with hsst5, hsst2 and hsst1 mRNAs being the most frequently expressed. soluble guanidylate cyclase, protein kinase G, and p42 MAP kinase activities. Moreover, these antiproliferative effects of hsst5 were described using cholecystokinin (CCK)-stimulated cells. Interestingly, we have previously shown the existence of CCK-B long and short isoforms and CCK-C receptors in the tumors analyzed in the present study (19) . Previously, Buscail et al. (13) have shown that hsst2 frequency of expression decreased with the tumor stage (3/6, 1/5, or 0/3 in Duke's stages B, C, and D respectively). Using RT-PCR and in situ hybridization, Laws et al. (14) have found that hsst2 mRNA was widely distributed in normal mucosa and stroma in 90% of samples. We found that hsst2 mRNA was expressed at a high frequency throughout all tumor stages without any decrease of expression in advanced stage tumors.
Our results suggest that the recently described SS analogs, particularly those specific to hsst5, could be considered as possible treatments even in advanced stages of colorectal cancer. However, immunohistological studies with specific antibodies are needed to confirm the presence of sst proteins.
